×
About 2,333 results

ALLMedicine™ Autosomal Dominant Polycystic Kidney Disease Center

Research & Reviews  855 results

Emerging non-pharmacological interventions in ADPKD: an update on dietary advices for c...
https://doi.org/10.1097/MNH.0000000000000734
Current Opinion in Nephrology and Hypertension; Meijer E, Gansevoort RT

Jul 15th, 2021 - Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) reach kidney failure at a median age of 58 years. There has been a strong interest in medical interventions to improve prognosis. With increasing understanding of the underlying pa...

The Effect of Smoking on Endothelial Dysfunction in Autosomal Dominant Polycystic Kidne...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8279153
Renal Failure; Gul CB, Yildiz A et. al.

Jul 14th, 2021 - In autosomal dominant polycystic kidney disease (ADPKD), endothelial dysfunction (ED) is common and occurs much earlier than kidney function impairment. The impact of smoking on ED in ADPKD patients has not been previously studied. The aim of this...

Natural-derived compounds and their mechanisms in potential autosomal dominant polycyst...
https://doi.org/10.1007/s10157-021-02111-x 10.2215/CJN.00330705 10.1053/j.ajkd.2015.07.037 10.1681/ASN.2013040398 10.2215/CJN.00190118 10.1007/s40265-015-0475-x 10.3892/mmr.2016.5616 10.1093/ndt/15.6.747 10.1152/ajprenal.00616.2011 10.1007/s11906-012-0316-1 10.1039/C7FO01253E 10.3389/fnut.2016.00048 10.1371/journal.pone.0131253 10.1111/bph.12443 10.1113/JP270933 10.1016/j.kint.2016.10.039 10.4062/biomolther.2015.024 10.7150/ijms.31075 10.1038/nrneph.2018.15 10.1152/ajprenal.00370.2003 10.1681/ASN.2013101037 10.1152/physiolgenomics.00027.2016 10.1089/jmf.2013.0061 10.1016/j.phrs.2020.104751 10.1038/sj.ki.5000054 10.1038/cr.2008.328 10.1016/j.bbadis.2011.06.012 10.2165/11534750-000000000-00000 10.1042/bj3480607 10.1038/nrm3311 10.1038/ncomms10856 10.1016/0092-8674(91)90446-6 10.1530/ERC-14-0284 10.1038/s41598-019-56847-4 10.1002/ptr.5631 10.1038/sj.onc.1205947 10.3892/or.2014.3585 10.4314/ahs.v15i1.13 10.1016/j.fitote.2009.08.020 10.1038/ncb2329 10.3390/molecules191220091 10.1038/s41598-019-41106-3 10.1074/jbc.M410670200 10.1182/blood-2002-05-1320 10.1038/sj.onc.1206048 10.1152/ajprenal.00419.2010 10.1002/ptr.6780 10.1016/j.intimp.2016.05.007 10.1093/carcin/bgg082 10.1039/np9931000301 10.1006/abbi.1995.1409 10.1016/j.pharmthera.2008.09.007 10.1016/j.bcp.2014.01.038 10.1080/10408398.2010.500245 10.1242/jcs.051011 10.1016/j.biopha.2018.02.139 10.1016/j.chembiol.2005.09.009 10.1073/pnas.0700499104 10.1681/ASN.2008030259 10.1016/S0092-8674(02)00716-X 10.1152/ajprenal.00329.2017 10.1097/FJC.0b013e3181bfaff3 10.1155/2013/963217 10.1093/ndt/gfw097 10.1093/ndt/gfw058 10.1038/nature08197 10.1083/jcb.200809167 10.1172/JCI64401 10.1016/j.bbrc.2010.05.160 10.1016/S0092-8674(01)00524-4
Clinical and Experimental Nephrology; Mahendran R, Lim SK et. al.

Jul 13th, 2021 - Autosomal dominant polycystic kidney disease (ADPKD) is a monogenic kidney disorder that impairs renal functions progressively leading to kidney failure. The disease affects between 1:400 and 1:1000 ratio of the people worldwide. It is caused by t...

see more →

Guidelines  12 results

International consensus statement on the diagnosis and management of autosomal dominant...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7136168
Nature Reviews. Nephrology; Gimpel C, Bergmann C et. al.

May 23rd, 2019 - These recommendations were systematically developed on behalf of the Network for Early Onset Cystic Kidney Disease (NEOCYST) by an international group of experts in autosomal dominant polycystic kidney disease (ADPKD) from paediatric and adult nep...

Clinical practice guideline monitoring children and young people with, or at risk of de...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6489289
BMC Nephrology; Dudley J, Winyard P et. al.

May 1st, 2019 - Autosomal Dominant Polycystic Kidney Disease (ADPKD) is thought to affect about 1 in 1000 people in the UK. ADPKD causes a progressive decline in kidney function, with kidney failure tending to occur in middle age. Children and young people with A...

KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Genetics and Genetic C...
https://doi.org/10.1016/j.semnephrol.2015.10.003
Seminars in Nephrology; Patel C, Tchan M et. al.

Dec 31st, 2015 - KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Genetics and Genetic Counseling.|2016|Patel C,Tchan M,Savige J,Mallett A,Tong A,|diagnostic imaging,genetics,genetics,

KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Imaging Approaches for...
https://doi.org/10.1016/j.semnephrol.2015.10.006
Seminars in Nephrology; Mai J, Lee VW et. al.

Dec 31st, 2015 - KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Imaging Approaches for Diagnosis.|2016|Mai J,Lee VW,Lopez-Vargas P,Vladica P,|methods,diagnosis,diagnostic imaging,genetics,

KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Diet and Lifestyle Man...
https://doi.org/10.1016/j.semnephrol.2015.10.008
Seminars in Nephrology; Campbell KL, Rangan GK et. al.

Dec 31st, 2015 - KHA-CARI Autosomal Dominant Polycystic Kidney Disease Guideline: Diet and Lifestyle Management.|2016|Campbell KL,Rangan GK,Lopez-Vargas P,Tong A,|administration & dosage,administration & dosage,physiology,complications,physiopathology,therapy,admi...

see more →

Drugs  2 results see all →

Clinicaltrials.gov  32 results

Curcumin Therapy to Treat Vascular Dysfunction in Children and Young Adults With ADPKD
https://clinicaltrials.gov/ct2/show/NCT02494141

Apr 7th, 2020 - Although often considered to be a disease of adults, complications of autosomal dominant polycystic kidney disease (ADPKD) begin in childhood. While ADPKD causes the continued growth of multiple kidney cysts that ultimately result in loss of kidne...

Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD
https://clinicaltrials.gov/ct2/show/NCT03203642

Mar 15th, 2020 - Safety and efficacy of 50mg tesevatinib in comparison to placebo in patients with autosomal dominant polycystic kidney disease (ADPKD) will be assessed. The primary purpose of this study is focused on evaluating the change from baseline in height-...

A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX
https://clinicaltrials.gov/ct2/show/NCT03366337

Dec 23rd, 2019 - This multi-center, open-label Phase 2 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with the following rare chronic kidney diseases (CKD): CKD associated with type 1 diabetes (T1D), IgA nephrop...

Daily Caloric Restriction and Intermittent Fasting in Overweight and Obese Adults With Autosomal Dominant Polycystic Kidney Disease
https://clinicaltrials.gov/ct2/show/NCT03342742

Sep 24th, 2019 - Autosomal dominant polycystic kidney disease (ADPKD) is characterized by development and continued growth of numerous fluid-filled renal cysts that ultimately result in renal failure. Similar to the general population, the prevalence of overweight...

Short-term Renal Hemodynamic Effects of Tolvaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
https://clinicaltrials.gov/ct2/show/NCT01336972

Mar 4th, 2019 - Renal function was assessed during screening with the estimated glomerular filtration rate (eGFR), which was calculated with the 4-variable modification of diet in renal disease (MDRD) equation using a minimum of 2 creatinine measurements. The eGF...

see more →

News  31 results

Fast Five Quiz: Autosomal Dominant Polycystic Kidney Disease Presentation and Diagnosis
https://www.medscape.com/viewarticle/950557

Jun 28th, 2021 - Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease worldwide. It is characterized by progressive development of renal cysts, hypertension, and destruction of the kidney parenchyma. Most patients with ...

Prolonged Antibiotics Cut Risk of Recurrence in Polycystic Kidney Disease
https://www.medscape.com/viewarticle/952953

Jun 10th, 2021 - A prolonged course of antibiotic therapy dramatically reduces the risk of recurrence in patients with renal cyst infections in the context of autosomal dominant polycystic kidney disease (ADPKD), a new study indicates. However, lipid-soluble antib...

FDA Boxed Warnings Updates: October 2018
https://www.mdedge.com/fedprac/article/176365/fda-actions/fda-boxed-warnings-updates-october-2018/page/0/2

Oct 3rd, 2018 - PROGRAF (TACROLIMUS) Edited boxed warning, May 2018 Increased risk for developing serious infections and malignancies with PROGRAF or other immunosuppressants that may lead to hospitalization or death [(see Warnings and Precautions 5. 1,5.

The Latest on Tolvaptan and Kidney Function Decline in Later-Stage ADPKD Patients
https://www.medscape.com/viewarticle/889380

Dec 6th, 2017 - Autosomal dominant polycystic kidney disease (ADPKD) now is the fourth leading cause of end-stage renal disease (ESRD). ADPKD develops when the genes encoding polycystin 1 and polycystin 2 are disrupted, which leads to cyst development and eventua...

Leukemia Drug Bosutinib Shows Promise for Inherited Kidney Disease
https://www.medscape.com/viewarticle/885015

Aug 30th, 2017 - NEW YORK (Reuters Health) - The tyrosine kinase inhibitor bosutinib, approved for chronic myeloid leukemia, reduced kidney growth rate in patients with autosomal dominant polycystic kidney disease (ADPKD) in a phase 2 study. ADPKD affects up to 1 ...

see more →

Patient Education  1 results see all →